[Comment] Combining top-ranked immunotherapeutics in lung cancer

Immunotherapy is becoming widely used in the treatment of non-small-cell lung cancer (NSCLC) in light of its impressive results in both first-line and second-line settings.1 However, doctors need to accept that not all patients can be treated with this approach and much still remains to be done to improve outcomes for patients with this lethal disease. Combining new immunotherapeutic agents with existing treatments such as chemotherapy or tyrosine kinases inhibitors can have both good and bad consequences.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research